Veradermics Trial Data and Servier’s Day One Deal
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Veradermics CEO Reid Waldman highlighted the company’s hair‑loss trial data and market hype.
- Servier Pharmaceuticals CEO David Lee detailed the acquisition of Day One Biopharmaceuticals and the firm’s M&A agenda.
- STAT hosted the discussion with reporters Allison DeAngelis, Adam Feuerstein, and Elaine Chen on its Readout Loud podcast.
- Artificial intelligence was discussed as a potential tool to make clinical trials run more smoothly.
Why it matters: Not enough in the article to say why this matters.
